Company Product Description Indication Status
Gilead Sciences Inc., of Foster City, Calif. Remdesivir RNA polymerase modulator COVID-19 infection FDA granted orphan drug designation
Inmed Pharmaceuticals Inc., of Vancouver, British Columbia INM-755 (cannabinol) Keratin modulator Epidermolysis bullosa CTA filed in the Netherlands to initiate second phase I trial in healthy volunteers assessing 2 strengths of study drug in 8 adults over 14-day treatment period
Prevail Therapeutics Inc., of New York PR-006 GRN gene stimulator Frontotemporal dementia FDA granted fast track designation to slow disease progression 
Samsung Bioepis Co. Ltd., of Incheon, Korea Ontruzant (trastuzumab-dttb) ERBB2 tyrosine kinase receptor inhibitor Breast/metastatic breast cancer; metastatic gastric cancer; gastroesophageal junction adenocarcinoma FDA approved 420-mg multidose vial of the biosimilar as adjuvant treatment
Shenzhen Chipscreen Biosciences Co. Ltd., of Shenzhen, China CS-112192 Dual JAK1/JAK3 tyrosine kinase inhibitor; serine threonine protein kinase TBK1 inhibitor Autoimmune diseases  China NMPA's Center for Drug Evaluation accepted IND

Notes

For more information about individual companies and/or products, see Cortellis.

No Comments